The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer
Abstract
Mechanisms controlling the emergence of lethal neuroendocrine prostate cancer (NEPC), especially those that are consequences of treatment-induced suppression of the androgen receptor (AR), remain elusive. Using a unique model of AR pathway inhibitor–resistant prostate cancer, we identified AR-dependent control of the neural transcription factor BRN2 (encoded by POU3F2) as a major driver of NEPC and aggressive tumor growth, both in vitro and in vivo. Mechanistic studies showed that AR directly suppresses BRN2 transcription, which is required for NEPC, and BRN2-dependent regulation of the NEPC marker SOX2. Underscoring its inverse correlation with classic AR activity in clinical samples, BRN2 expression was highest in NEPC tumors and was significantly increased in castration-resistant prostate cancer compared with adenocarcinoma, especially in patients with low serum PSA. These data reveal a novel mechanism of AR-dependent control of NEPC and suggest that targeting BRN2 is a strategy to treat or prevent neuroendocrine differentiation in prostate tumors. Significance: Understanding the contribution of the AR to the emergence of highly lethal, drug-resistant NEPC is critical for better implementation of current standard-of-care therapies and novel drug design. Our first-in-field data underscore the consequences of potent AR inhibition in prostate tumors, revealing a novel mechanism of AR-dependent control of neuroendocrine differentiation, and uncover BRN2 as a potential therapeutic target to prevent emergence of NEPC. Cancer Discov; 7(1); 54–71. ©2016 AACR. This article is highlighted in the In This Issue feature, p. 1
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Beltran, H., Prandi, D., Mosquera, J. M., Benelli, M., Puca, L., Cyrta, J., Marotz, C., Giannopoulou, E., Chakravarthi, B. V. S. K., Varambally, S., et al. (2016) · Nature Medicine · doi:10.1038/nm.4045 · Cited by 1,685
Self-citationSOX2 Functions to Maintain Neural Progenitor Identity
Graham, V., Khudyakov, J., Ellis, P., & Pevny, L. (2003) · Neuron · doi:10.1016/s0896-6273(03)00497-5 · Cited by 1,341
Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
Beltran, H., Rickman, D. S., Park, K., Chae, S. S., Sboner, A., MacDonald, T. Y., Wang, Y., Sheikh, K. L., Terry, S., Tagawa, S. T., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0130 · Cited by 999
Self-citationGlucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
Arora, V. K., Schenkein, E., Murali, R., Subudhi, S. K., Wongvipat, J., Balbas, M. D., Shah, N., Cai, L., Efstathiou, E., Logothetis, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.11.012 · Cited by 986
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
Asangani, I. A., Dommeti, V. L., Wang, X., Malik, R., Cieslik, M., Yang, R., Escara-Wilke, J., Wilder-Romans, K., Dhanireddy, S., Engelke, C., et al. (2014) · Nature · doi:10.1038/nature13229 · Cited by 927
Shappell, S. B., Thomas, G. V., Roberts, R. L., Herbert, R., Ittmann, M. M., Rubin, M. A., Humphrey, P. A., Sundberg, J. P., Rozengurt, N., Barrios, R., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0946 · Cited by 598
Self-citationJoseph, J. D., Lu, N., Qian, J., Sensintaffar, J., Shao, G., Brigham, D., Moon, M., Maneval, E. C., Chen, I., Darimont, B., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0226 · Cited by 578
Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation
Epstein, J. I., Amin, M. B., Beltran, H., Lotan, T. L., Mosquera, J.-M., Reuter, V. E., Robinson, B. D., Troncoso, P., & Rubin, M. A. (2014) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000208 · Cited by 569
Self-citationKorpal, M., Korn, J. M., Gao, X., Rakiec, D. P., Ruddy, D. A., Doshi, S., Yuan, J., Kovats, S. G., Kim, S., Cooke, V. G., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0142 · Cited by 561
Azad, A. A., Volik, S. V., Wyatt, A. W., Haegert, A., Le Bihan, S., Bell, R. H., Anderson, S. A., McConeghy, B., Shukin, R., Bazov, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2666 · Cited by 478
Self-citationPathobiology of autochthonous prostate cancer in a pre‐clinical transgenic mouse model
Kaplan‐Lefko, P. J., Chen, T., Ittmann, M. M., Barrios, R. J., Ayala, G. E., Huss, W. J., Maddison, L. A., Foster, B. A., & Greenberg, N. M. (2003) · The Prostate · doi:10.1002/pros.10215 · Cited by 438
Aggressive Variants of Castration-Resistant Prostate Cancer
Beltran, H., Tomlins, S., Aparicio, A., Arora, V., Rickman, D., Ayala, G., Huang, J., True, L., Gleave, M. E., Soule, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3309 · Cited by 420
Self-citationN-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells
Lee, J. K., Phillips, J. W., Smith, B. A., Park, J. W., Stoyanova, T., McCaffrey, E. F., Baertsch, R., Sokolov, A., Meyerowitz, J. G., Mathis, C., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.001 · Cited by 407
Overcoming mutation-based resistance to antiandrogens with rational drug design
Balbas, M. D., Evans, M. J., Hosfield, D. J., Wongvipat, J., Arora, V. K., Watson, P. A., Chen, Y., Greene, G. L., Shen, Y., & Sawyers, C. L. (2013) · eLife · doi:10.7554/elife.00499 · Cited by 397
Lin, D., Wyatt, A. W., Xue, H., Wang, Y., Dong, X., Haegert, A., Wu, R., Brahmbhatt, S., Mo, F., Jong, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2921-t · Cited by 364
Self-citationRb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma
Tan, H.-L., Sood, A., Rahimi, H. A., Wang, W., Gupta, N., Hicks, J., Mosier, S., Gocke, C. D., Epstein, J. I., Netto, G. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1982 · Cited by 346
Tarhini, A. A., Edington, H., Butterfield, L. H., Lin, Y., Shuai, Y., Tawbi, H., Sander, C., Yin, Y., Holtzman, M., Johnson, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087705 · Cited by 310
The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer
Akamatsu, S., Wyatt, A. W., Lin, D., Lysakowski, S., Zhang, F., Kim, S., Tse, C., Wang, K., Mo, F., Haegert, A., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.012 · Cited by 279
Self-citationDominguez, M. H., Ayoub, A. E., & Rakic, P. (2013) · Cerebral Cortex · doi:10.1093/cercor/bhs252 · Cited by 215
Pinner, S., Jordan, P., Sharrock, K., Bazley, L., Collinson, L., Marais, R., Bonvin, E., Goding, C., & Sahai, E. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0781 · Cited by 202
Lodato, M. A., Ng, C. W., Wamstad, J. A., Cheng, A. W., Thai, K. K., Fraenkel, E., Jaenisch, R., & Boyer, L. A. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003288 · Cited by 199
Lapuk, A. V., Wu, C., Wyatt, A. W., McPherson, A., McConeghy, B. J., Brahmbhatt, S., Mo, F., Zoubeidi, A., Anderson, S., Bell, R. H., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4047 · Cited by 196
Self-citationSOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell
Jia, X., Li, X., Xu, Y., Zhang, S., Mou, W., Liu, Y., Liu, Y., Lv, D., Liu, C.-H., Tan, X., et al. (2011) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjr002 · Cited by 194
Ferraldeschi, R., Welti, J., Luo, J., Attard, G., & de Bono, J. S. (2015) · Oncogene · doi:10.1038/onc.2014.115 · Cited by 192
Sox2 Is an Androgen Receptor-Repressed Gene That Promotes Castration-Resistant Prostate Cancer
Kregel, S., Kiriluk, K. J., Rosen, A. M., Cai, Y., Reyes, E. E., Otto, K. B., Tom, W., Paner, G. P., Szmulewitz, R. Z., & Vander Griend, D. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053701 · Cited by 177
Melanoma cell invasiveness is regulated by miR‐211 suppression of the BRN2 transcription factor
Boyle, G. M., Woods, S. L., Bonazzi, V. F., Stark, M. S., Hacker, E., Aoude, L. G., Dutton‐Regester, K., Cook, A. L., Sturm, R. A., & Hayward, N. K. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00849.x · Cited by 177
Li, Y., Donmez, N., Sahinalp, C., Xie, N., Wang, Y., Xue, H., Mo, F., Beltran, H., Gleave, M., Wang, Y., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.04.028 · Cited by 177
Self-citationZhang, X., Coleman, I. M., Brown, L. G., True, L. D., Kollath, L., Lucas, J. M., Lam, H.-M., Dumpit, R., Corey, E., Chéry, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0157 · Cited by 176
BURCHARDT, T., BURCHARDT, M., CHEN, M.-W., CAO, Y., DE LA TAILLE, A., SHABSIGH, A., HAYEK, O., DORAI, T., & BUTTYAN, R. (1999) · Journal of Urology · doi:10.1016/s0022-5347(05)68241-9 · Cited by 170
Catena, R., Tiveron, C., Ronchi, A., Porta, S., Ferri, A., Tatangelo, L., Cavallaro, M., Favaro, R., Ottolenghi, S., Reinbold, R., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405514200 · Cited by 160
Hu, C.-D., Choo, R., & Huang, J. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00090 · Cited by 159
Svensson, C., Ceder, J. A., Iglesias‐Gato, D., Chuan, Y.-C., Pang, S., Bjartell, A. S., Merino-Martinez, R., Bott, L., Helczynski, L., Ulmert, D., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt921 · Cited by 159
Self-citationModeling a Lethal Prostate Cancer Variant with Small-Cell Carcinoma Features
Tzelepi, V., Zhang, J., Lu, J.-F., Kleb, B., Wu, G., Wan, X., Hoang, A. G., Efstathiou, E., Sircar, K., Navone, N. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1867 · Cited by 152
Understanding the Lethal Variant of Prostate Cancer: Power of Examining Extremes
Aparicio, A. M., Logothetis, C. J., & Maity, S. N. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0259 · Cited by 137
Hubbard, G. K., Mutton, L. N., Khalili, M., McMullin, R. P., Hicks, J. L., Bianchi-Frias, D., Horn, L. A., Kulaç, İ., Moubarek, M. S., Nelson, P. S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3280 · Cited by 136
Expression of Pluripotent Stem Cell Reprogramming Factors by Prostate Tumor Initiating Cells
Bae, K., Su, Z. Z., Frye, C., McClellan, S., Allan, R. W., Andrejewski, J. T., Kelley, V., Jorgensen, M., Steindler, D. A., Vieweg, J., et al. (2010) · The Journal of Urology · doi:10.1016/j.juro.2009.12.092 · Cited by 126
The Brn-2 Transcription Factor Links Activated BRAF to Melanoma Proliferation
GOODALL, J. C., Wellbrock, C., Dexter, T. J., Roberts, K., Marais, R., & Goding, C. R. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2923-2931.2004 · Cited by 126
Expression of The Embryonic Stem Cell Transcription Factor SOX2 in Human Skin
Laga, A. C., Lai, C.-Y., Zhan, Q., Huang, S. J., Velázquez, E. F., Yang, Q., Hsu, M., & Murphy, G. F. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090495 · Cited by 118
Kuruma, H., Matsumoto, H., Shiota, M., Bishop, J. L., Lamoureux, F., Thomas, C., Briere, D. M., Los, G., Gleave, M. E., Fanjul, A. N., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0798 · Cited by 114
Self-citationDailey, L., & Basilico, C. (2001) · Journal of Cellular Physiology · doi:10.1002/1097-4652(2001)9999:9999<000::aid-jcp1046>3.0.co;2-y · Cited by 106
Wee, Z. N., Li, Z., Lee, P. L., Lee, S. T., Lim, Y. P., & Yu, Q. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.045 · Cited by 106
Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway
Chen, H., Sun, Y., Wu, C., Magyar, C. E., Li, X., Liang Cheng, C., Yao, J. L., Shen, S. S., Osunkoya, A. O., Liang, C. Y., et al. (2012) · Endocrine Related Cancer · doi:10.1530/erc-11-0368 · Cited by 98
Sox2 Expression in Pulmonary Non-small Cell and Neuroendocrine Carcinomas
Sholl, L. M., Long, K. B., & Hornick, J. L. (2009) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e3181b16b88 · Cited by 97
Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer
Wyatt, A. W., Mo, F., Wang, K., McConeghy, B., Brahmbhatt, S., Jong, L., Mitchell, D. M., Johnston, R. L., Haegert, A., Li, E., et al. (2014) · Genome Biology · doi:10.1186/s13059-014-0426-y · Cited by 82
Self-citationIwafuchi, M., Yoshida, Y., Onichtchouk, D., Leichsenring, M., Driever, W., Takemoto, T., Uchikawa, M., Kamachi, Y., & Kondoh, H. (2010) · Developmental Biology · doi:10.1016/j.ydbio.2010.12.027 · Cited by 72
Lin, F., Lin, P., Zhao, D., Chen, Y., Xiao, L., Qin, W., Li, D., Chen, H., Zhao, B., Zou, H., et al. (2012) · Cell Proliferation · doi:10.1111/j.1365-2184.2012.00812.x · Cited by 65
Barton, B. E., Murphy, T. F., Shu, P., Huang, H. F. S., Meyenhofen, M., & Barton, A. B. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1183.3.10 · Cited by 63
Small, E. J., Huang, J., YOUNGREN, J. F., Sokolov, A., Aggarwal, R. R., THOMAS, G. V., True, L. D., Zhang, L., Foye, A., Alumkal, J. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.5003 · Cited by 61
Self-citationIshii, J., Sato, H., Sakaeda, M., Shishido‐Hara, Y., Hiramatsu, C., Kamma, H., Shimoyamada, H., Fujiwara, M., Endo, T., Aoki, I., et al. (2013) · Pathology International · doi:10.1111/pin.12042 · Cited by 50
Berlin, I., Denat, L., Steunou, A., Puig, I., Champeval, D., Colombo, S., Roberts, K., Bonvin, E., Bourgeois, Y., Davidson, I., et al. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06257-11 · Cited by 43
Sakaeda, M., Sato, H., Ishii, J., Miyata, C., Kamma, H., Shishido‐Hara, Y., Shimoyamada, H., Fujiwara, M., Endo, T., Tanaka, R., et al. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.2 · Cited by 29
Morise, M., Hishida, T., Takahashi, A., Yoshida, J., Ohe, Y., Nagai, K., & Ishii, G. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-1985-3 · Cited by 16
Cited by
Aggarwal, R., Huang, J., Alumkal, J. J., Zhang, L., Feng, F. Y., Thomas, G. V., Weinstein, A. S., Friedl, V., Zhang, C., Witte, O. N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6880 · Cited by 810
Self-citationThe great escape: tumour cell plasticity in resistance to targeted therapy
Boumahdi, S., & de Sauvage, F. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0044-1 · Cited by 761
Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B. H., Clarke, N., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.06.002 · Cited by 642
Self-citationWidespread and Functional RNA Circularization in Localized Prostate Cancer
Chen, S., Huang, V., Xu, X., Livingstone, J., Soares, F., Jeon, J., Zeng, Y., Hua, J. T., Petricca, J., Guo, H., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.025 · Cited by 544
Self-citationLabrecque, M. P., Coleman, I. M., Brown, L. G., True, L. D., Kollath, L., Lakely, B., Nguyen, H. M., Yang, Y. C., da Costa, R. M. G., Kaipainen, A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci128212 · Cited by 464
Self-citation
Metadata
- Authors
- Bishop, J. L., Thaper, D., Vahid, S., Davies, A., Ketola, K., Kuruma, H., Jama, R., Nip, K. M., Angeles, A., Johnson, F., Wyatt, A. W., Fazli, L., Gleave, M. E., Lin, D., Rubin, M. A., Collins, C. C., Wang, Y., Beltran, H., & Zoubeidi, A.
- Venue
- Cancer Discovery
- Published
- 2017-01-01
- Volume
- 7
- Issue
- 1
- Pages
- 54-71
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2540786849
- Cited by
- 418
- References
- 55
- FWCI
- 21.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.